The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Evolution of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Cyclooxygenase (COX) Inhibition and Beyond
Open accessAbstract
Purpose. NSAIDs constitute an important class of drugs with therapeutic applications that have spanned several centuries. Treatment of inflammatory conditions such as rheumatoid arthritis (RA) and osteoarthritis (OA) starting from the classic drug aspirin to the recent rise and fall of selective COX-2 inhibitors has provided an enthralling evolution. Efforts to discover an ultimate magic bullet to treat inflammation continues to be an important drug design challenge. This review traces the origins of NSAIDs, their mechanism of action at the molecular level such as cyclooxygenase (COX) inhibition, development of selective COX-2 inhibitors, their adverse cardiovascular effects, and some recent developments targeted to the design of effective anti-inflammatory agents with reduced side effects. Methods. Literature data is presented describing important discoveries pertaining to the sequential development of classical NSAIDs and then selective COX-2 inhibitors, their mechanism of action, the structural basis for COX inhibition, and recent discoveries. Results. A brief history of the development of NSAIDs and the market withdrawal of selective COX-2 inhibitors is explained, followed by the description of prostaglandin biosynthesis, COX isoforms, structure and function. The structural basis for COX-1 and COX-2 inhibition is described along with methods used to evaluate COX-1/COX-2 inhibition. This is followed by a section that encompasses the major chemical classes of selective COX-2 inhibitors. The final section describes briefly some of the recent advances toward developing effective anti-inflammatory agents such as nitric oxide donor NO-NSAIDs, dual COX/LOX inhibitors and anti-TNF therapy. Conclusions. A great deal of progress has been made toward developing novel anti-inflammatory agents. In spite of the tremendous advances in the last decade, the design and development of a safe, effective and economical therapy for treating inflammatory conditions still presents a major challenge.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs
VANE, J. R. (1971) · Nature New Biology · doi:10.1038/newbio231232a0 · Cited by 8,605
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Silverstein, F. E., Faich, G., Goldstein, J. L., Simon, L. S., Pincus, T., Whelton, A., Makuch, R., Eisen, G., Agrawal, N. M., Stenson, W. F., et al. (2000) · JAMA · doi:10.1001/jama.284.10.1247 · Cited by 3,154
Cyclooxygenases: Structural, cellular, and molecular biology
Smith, W. L., DeWitt, D. L., & Garavito, R. M. (2000) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.69.1.145 · Cited by 2,925
Vane, J. R., Bakhle, Y. S., & Botting, R. M. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.97 · Cited by 2,734
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
Chandrasekharan, N. V., Dai, H., Roos, K. L. T., Evanson, N. K., Tomsik, J., Elton, T. S., & Simmons, D. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162468699 · Cited by 1,989
Penning, T. D., Talley, J. J., Bertenshaw, S. R., Carter, J. S., Collins, P. W., Docter, S., Graneto, M. J., Lee, L. F., Malecha, J. W., Miyashiro, J. M., et al. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm960803q · Cited by 1,965
Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents
Kurumbail, R. G., Stevens, A. M., Gierse, J. K., McDonald, J. J., Stegeman, R. A., Pak, J. Y., Gildehaus, D., iyashiro, J. M., Penning, T. D., Seibert, K., et al. (1996) · Nature · doi:10.1038/384644a0 · Cited by 1,917
Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors
Mukherjee, D. (2001) · JAMA · doi:10.1001/jama.286.8.954 · Cited by 1,741
Xie, W. L., Chipman, J. G., Robertson, D. L., Erikson, R. L., & Simmons, D. L. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.7.2692 · Cited by 1,707
The Coxibs, Selective Inhibitors of Cyclooxygenase-2
FitzGerald, G. A., & Patrono, C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108093450607 · Cited by 1,565
Seibert, K., Zhang, Y., Leahy, K., Hauser, S., Masferrer, J., Perkins, W., Lee, L., & Isakson, P. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.25.12013 · Cited by 1,551
Warner, T. D., Giuliano, F., Vojnovic, I., Bukasa, A., Mitchell, J. A., & Vane, J. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.13.7563 · Cited by 1,519
Multiple Female Reproductive Failures in Cyclooxygenase 2–Deficient Mice
Lim, H., Paria, B. C., Das, S. K., Dinchuk, J. E., Langenbach, R., Trzaskos, J. M., & Dey, S. K. (1997) · Cell · doi:10.1016/s0092-8674(00)80402-x · Cited by 1,430
McAdam, B. F., Catella-Lawson, F., Mardini, I. A., Kapoor, S., Lawson, J. A., & FitzGerald, G. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.272 · Cited by 1,305
The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1
Picot, D., Loll, P. J., & Garavito, R. M. (1994) · Nature · doi:10.1038/367243a0 · Cited by 1,265
Meade, E. A., Smith, W. L., & DeWitt, D. L. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53294-4 · Cited by 1,256
Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse
Morham, S. G., Langenbach, R., Loftin, C. D., Tiano, H. F., Vouloumanos, N., Jennette, J. C., Mahler, J. F., Kluckman, K. D., Ledford, A., Lee, C. A., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90125-6 · Cited by 1,082
Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II
Dinchuk, J. E., Car, B. D., Focht, R. J., Johnston, J. J., Jaffee, B. D., Covington, M. B., Contel, N. R., Eng, V. M., Collins, R. J., Czerniak, P. M., et al. (1995) · Nature · doi:10.1038/378406a0 · Cited by 969
Lee, S. H., Soyoola, E., Chanmugam, P., Hart, S., Sun, W., Zhong, H., Liou, S., Simmons, D., & Hwang, D. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)35698-9 · Cited by 811
Pharmacological analysis of cyclooxygenase-1 in inflammation
Smith, C. J., Zhang, Y., Koboldt, C. M., Muhammad, J., Zweifel, B. S., Shaffer, A., Talley, J. J., Masferrer, J. L., Seibert, K., & Isakson, P. C. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13313 · Cited by 807
Antman, E. M., Bennett, J. S., Daugherty, A., Furberg, C., Roberts, H., & Taubert, K. A. (2007) · Circulation · doi:10.1161/circulationaha.106.181424 · Cited by 804
Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases
Hu, J., Van den Steen, P. E., Sang, Q.-X. A., & Opdenakker, G. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2308 · Cited by 795
Prostaglandin Endoperoxide H Synthases-1 and -2
Smith, W. L., & Dewitt, D. L. (1996) · Advances in Immunology · doi:10.1016/s0065-2776(08)60430-7 · Cited by 711
Schnitzer, T. J., Burmester, G. R., Mysler, E., Hochberg, M. C., Doherty, M., Ehrsam, E., Gitton, X., Krammer, G., Mellein, B., Matchaba, P., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16893-1 · Cited by 701
Hsu, A.-L., Ching, T.-T., Wang, D.-S., Song, X., Rangnekar, V. M., & Chen, C.-S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.15.11397 · Cited by 671
Purification of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes.
Miyamoto, T., Ogino, N., Yamamoto, S., & Hayaishi, O. (1976) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)33534-2 · Cited by 663
Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration
Teismann, P., Tieu, K., Choi, D.-K., Wu, D.-C., Naini, A., Hunot, S., Vila, M., Jackson-Lewis, V., & Przedborski, S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0837397100 · Cited by 660
Talley, J. J., Brown, D. L., Carter, J. S., Graneto, M. J., Koboldt, C. M., Masferrer, J. L., Perkins, W. E., Rogers, R. S., Shaffer, A. F., Zhang, Y. Y., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990577v · Cited by 638
Mizuno, H., Sakamoto, C., Matsuda, K., Wada, K., Uchida, T., Noguchi, H., Akamatsu, T., & Kasuga, M. (1997) · Gastroenterology · doi:10.1053/gast.1997.v112.pm9024292 · Cited by 637
Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2
Luong, C., Miller, A., Barnett, J., Chow, J., Ramesha, C., & Browner, M. F. (1996) · Nature Structural Biology · doi:10.1038/nsb1196-927 · Cited by 618
DeWitt, D. L., & Smith, W. L. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.5.1412 · Cited by 596
Anti-TNF-α therapies: the next generation
Palladino, M. A., Bahjat, F. R., Theodorakis, E. A., & Moldawer, L. L. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1175 · Cited by 576
Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process
Wallace, J. L., Keenan, C. M., & Granger, D. N. (1990) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1990.259.3.g462 · Cited by 547
Characterization of inducible cyclooxygenase in rat brain
Breder, C. D., Dewitt, D., & Kraig, R. P. (1995) · Journal of Comparative Neurology · doi:10.1002/cne.903550208 · Cited by 533
Cannon, C. P., Curtis, S. P., FitzGerald, G. A., Krum, H., Kaur, A., Bolognese, J. A., Reicin, A. S., Bombardier, C., Weinblatt, M. E., van der Heijde, D., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69666-9 · Cited by 522
COX-2 and beyond: approaches to prostaglandin inhibition in human disease
FitzGerald, G. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1225 · Cited by 518
Sulindac for polyposis of the colon
Waddell, W. R., & Loughry, R. W. (1983) · Journal of Surgical Oncology · doi:10.1002/jso.2930240119 · Cited by 513
Solomon, D. H., Schneeweiss, S., Glynn, R. J., Kiyota, Y., Levin, R., Mogun, H., & Avorn, J. (2004) · Circulation · doi:10.1161/01.cir.0000127578.21885.3e · Cited by 509
Acetaminophen (paracetamol) is a selective cyclooxygenase‐2 inhibitor in man
Hinz, B., Cheremina, O., & Brune, K. (2008) · The FASEB Journal · doi:10.1096/fj.07-8506com · Cited by 478
The Role of Arachidonic Acid Oxygenation Products in Pain and Inflammation
Davies, P. (1984) · Annual Review of Immunology · doi:10.1146/annurev.immunol.2.1.335 · Cited by 467
Breitner, J. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00049-k · Cited by 466
Kargman, S., Charleson, S., Cartwright, M., Frank, J., Riendeau, D., Mancini, J., Evans, J., & O'Neill, G. (1996) · Gastroenterology · doi:10.1053/gast.1996.v111.pm8690211 · Cited by 462
Charlier, C., & Michaux, C. (2003) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(03)00115-6 · Cited by 432
Merlie, J. P., Fagan, D., Mudd, J., & Needleman, P. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)68959-8 · Cited by 429
Prasit, P., Wang, Z., Brideau, C., Chan, C.-C., Charleson, S., Cromlish, W., Ethier, D., Evans, J. F., Ford-Hutchinson, A. W., Gauthier, J. Y., et al. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00288-7 · Cited by 429
Eicosanoids and the gastrointestinal tract
Eberhart, C. E., & Dubois, R. N. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90296-1 · Cited by 414
Dexamethasone inhibits mitogen induction of the TIS10 prostaglandin synthase/cyclooxygenase gene.
Kujubu, D. A., & Herschman, H. R. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42398-8 · Cited by 402
Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice.
Masferrer, J. L., Zweifel, B. S., Seibert, K., & Needleman, P. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114850 · Cited by 402
Cyclooxygenase-2 (COX-2)–Independent Anticarcinogenic Effects of Selective COX-2 Inhibitors
Grösch, S., Maier, T. J., Schiffmann, S., & Geisslinger, G. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj206 · Cited by 400
Inflammation and immune regulation by 12/15-lipoxygenases
Kühn, H., & O’Donnell, V. B. (2006) · Progress in Lipid Research · doi:10.1016/j.plipres.2006.02.003 · Cited by 398
Chan, C.-C., Boyce, S., Brideau, C., Charleson, S., Cromlish, W., Ethier, D., Evans, J., Ford-Hutchinson, A. W., Forrest, M. J., Gauthier, J. Y., et al. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)34934-1 · Cited by 398
Adderley, S. R., & Fitzgerald, D. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.8.5038 · Cited by 371
Mechanism of Action of Acetaminophen: Is There a Cyclooxygenase 3?
Botting, R. M. (2000) · Clinical Infectious Diseases · doi:10.1086/317520 · Cited by 350
Adverse Cardiovascular Effects of the Coxibs
Dogné, J.-M., Supuran, C. T., & Pratico, D. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0402059 · Cited by 344
Nitric Oxide in the Vasculature: Physiology and Pathophysiology
MONCADA, S. (1997) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1997.tb51989.x · Cited by 340
Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function
Cheng, Y. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27540 · Cited by 339
Zhang, J., Ding, E. L., & Song, Y. (2006) · JAMA · doi:10.1001/jama.296.13.jrv60015 · Cited by 332
Prostaglandins, Aspirin-like Drugs and the Oedema of Inflammation
MONCADA, S., FERREIRA, S. H., & VANE, J. R. (1973) · Nature · doi:10.1038/246217a0 · Cited by 312
TNFα blockade in human diseases: Mechanisms and future directions
Wong, M., Ziring, D., Korin, Y., Desai, S., Kim, S., Lin, J., Gjertson, D., Braun, J., Reed, E., & Singh, R. R. (2008) · Clinical Immunology · doi:10.1016/j.clim.2007.08.013 · Cited by 307
Fiorucci, S., Meli, R., Bucci, M., & Cirino, G. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00747-x · Cited by 285
Mitchell, J. A., & Warner, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1929 · Cited by 279
Elliott, S. N., McKnight, W., Cirino, G., & Wallace, J. L. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90341-0 · Cited by 262
Acetaminophen and the Cyclooxygenase-3 Puzzle: Sorting out Facts, Fictions, and Uncertainties
Kis, B., Snipes, J. A., & Busija, D. W. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.085431 · Cited by 250
The mode of action of aspirin and similar compounds
Vane, J. R. (1976) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(76)90181-0 · Cited by 229
Kotilinek, L. A., Westerman, M. A., Wang, Q., Panizzon, K., Lim, G. P., Simonyi, A., Lesne, S., Falinska, A., Younkin, L. H., Younkin, S. G., et al. (2008) · Brain · doi:10.1093/brain/awn008 · Cited by 220
Loftin, C. D., Trivedi, D. B., Tiano, H. F., Clark, J. A., Lee, C. A., Epstein, J. A., Morham, S. G., Breyer, M. D., Nguyen, M., Hawkins, B. M., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.3.1059 · Cited by 219
Primary structure of sheep prostaglandin endoperoxide synthase deduced from cDNA sequence
Yokoyama, C., Takai, T., & Tanabe, T. (1988) · FEBS Letters · doi:10.1016/0014-5793(88)80847-0 · Cited by 218
Habeeb, A. G., Praveen Rao, P. N., & Knaus, E. E. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010153c · Cited by 215
Self-citationAngiotensin II attenuates renal cortical cyclooxygenase-2 expression
Cheng, H.-F., Wang, J.-L., Zhang, M.-Z., Miyazaki, Y., Ichikawa, I., McKanna, J. A., & Harris, R. C. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5505 · Cited by 200
Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors
Katori, M., & Majima, M. (2000) · Inflammation Research · doi:10.1007/s000110050605 · Cited by 193
Riendeau, D., Charleson, S., Cromlish, W., Mancini, J. A., Wong, E., & Guay, J. (1997) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-75-9-1088 · Cited by 186
Bhattacharyya, D. K., Lecomte, M., Rieke, C. J., Garavito, R. M., & Smith, W. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.4.2179 · Cited by 185
5 Selective Inhibitors of Cyclooxygenase-2 (COT-2)
Talley, J. J. (1999) · Progress in Medicinal Chemistry · doi:10.1016/s0079-6468(08)70048-1 · Cited by 178
Tamblyn, R., Berkson, L., Dauphinee, W. D., Gayton, D., Grad, R., Huang, A., Isaac, L., McLeod, P., & Snell, L. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-6-199709150-00003 · Cited by 177
Li, J. J., Anderson, G. D., Burton, E. G., Cogburn, J. N., Collins, J. T., Garland, D. J., Gregory, S. A., Huang, H.-C., & Isakson, P. C. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00022a023 · Cited by 177
Geronikaki, A. A., Lagunin, A. A., Hadjipavlou-Litina, D. I., Eleftheriou, P. T., Filimonov, D. A., Poroikov, V. V., Alam, I., & Saxena, A. K. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701496h · Cited by 176
Zhu, J. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.23.1745 · Cited by 166
A diclofenac derivative without ulcerogenic properties
Wallace, J. L., Reuter, B., Cicala, C., McKnight, W., Grisham, M., & Cirino, G. (1994) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)90136-8 · Cited by 161
Feng, Z.-H., Wang, T.-G., Li, D.-D., Fung, P., Wilson, B. C., Liu, B., Ali, S. F., Langenbach, R., & Hong, J.-S. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00704-8 · Cited by 160
Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis
Herman, A. G., & Moncada, S. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi333 · Cited by 156
Potential cardioprotective actions of no-releasing aspirin
Wallace, J. L., Ignarro, L. J., & Fiorucci, S. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd794 · Cited by 144
Mancini, J. A., Riendeau, D., Falgueyret, J., Vickers, P. J., & O’Neill, G. P. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.49.29372 · Cited by 141
de Gaetano, G., Donati, M. B., & Cerletti, C. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00077-4 · Cited by 138
Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase‐2
Esser, R. E., Berry, C., Du, Z., Dawson, J., Fox, A., Fujimoto, R. A., Haston, W. O., Kimble, E. F., Koehler, J., Peppard, J., et al. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706078 · Cited by 136
Constitutive Cyclooxygenase-2 Expression in Healthy Human and Rabbit Gastric Mucosa
Zimmermann, K. C., Sarbia, M., Schrör, K., & Weber, A. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.3.536 · Cited by 121
The fight against rheumatism: from willow bark to COX-1 sparing drugs.
Vane, J. R. (2000) · PubMed · Cited by 115
Velázquez, C. A., Rao, P. P. N., & Knaus, E. E. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050211k · Cited by 111
Self-citationLicofelone--clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis
Alvaro-Gracia, J. M. (2004) · British journal of rheumatology · doi:10.1093/rheumatology/keh105 · Cited by 110
Rao, P. P. N., Amini, M., Li, H., Habeeb, A. G., & Knaus, E. E. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0302391 · Cited by 107
Self-citationChavez, M. L., & DeKorte, C. J. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80110-8 · Cited by 88
Pairet, M., & van Ryn, J. (1998) · Inflammation Research · doi:10.1007/s000110050289 · Cited by 87
Inhibitors of cyclooxygenase-2 and 5-lipoxygenase
(1997) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.7.9.1041 · Cited by 86
The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats
Reksidler, A. B., Lima, M. M. S., Zanata, S. M., Machado, H. B., Cunha, C. D., Andreatini, R., Tufik, S., & Vital, M. A. B. F. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.12.032 · Cited by 79
Ranatunge, R. R., Augustyniak, M. E., Bandarage, U. K., Earl, R. A., Ellis, J. L., Garvey, D. S., Janero, D. R., Letts, L. G., Martino, A. M., Murty, M. G., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030276s · Cited by 78
Cardioprotective effects of glyceryl trinitrate: beyond vascular nitrate tolerance
Csont, T., & Ferdinandy, P. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.10.001 · Cited by 78
Cyclo-Oxygenase-2 and its Inhibition in Cancer: Is There a Role?
Liao, Z. X., Mason, K. A., & Milas, L. (2007) · Drugs · doi:10.2165/00003495-200767060-00001 · Cited by 77
Update on Cyclooxygenase-2 Inhibitors
Harris, R. C., & Breyer, M. D. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00890805 · Cited by 75
Pilbeam, C. C., FALL, P. M., Alander, C. B., & Raisz, L. G. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.8.1198 · Cited by 68
2,3-Diarylbenzopyran derivatives as a novel class of selective cyclooxygenase-2 inhibitors
Joo, Y. H., Kim, J., Kang, S., Noh, M., Ha, J., Choi, J. K., Lim, K., Lee, C. H., & Chung, S. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00952-6 · Cited by 66
Muscará, M. N., McKnight, W., Soldato, P. D., & Wallace, J. L. (1998) · Life Sciences · doi:10.1016/s0024-3205(98)00072-1 · Cited by 65
Velázquez, C. A., Rao, P. P. N., McDonald, R., & Knaus, E. E. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.02.034 · Cited by 63
Self-citationEuropean Medicines Agency gives favourable ruling on NSAIDs
Watson, R. (2006) · BMJ · doi:10.1136/bmj.333.7574.873-a · Cited by 58
Habeeb, A. G., Rao, P. P. N., & Knaus, E. E. (2000) · Drug Development Research · doi:10.1002/ddr.9 · Cited by 56
Self-citationCyclooxygenase‐2 and Tumor Biology
Kanaoka, S., Takai, T., & Yoshida, K. (2006) · Advances in clinical chemistry · doi:10.1016/s0065-2423(06)43002-x · Cited by 45
Activity and potential role of licofelone in the management of osteoarthritis
Cicero, A. F. G., & Laghi, L. (2007) · Clinical Interventions in Aging · doi:10.2147/ciia.2007.2.1.73 · Cited by 30
Is there a Future for Cyclo-Oxygenase Inhibitors in Alzheimer???s Disease?
Ho, L., Qin, W., Stetka, B., & Pasinetti, G. M. (2006) · CNS Drugs · doi:10.2165/00023210-200620020-00001 · Cited by 29
THIERS, B. H. (2007) · Yearbook of Dermatology and Dermatologic Surgery · doi:10.1016/s0093-3619(08)70536-7 · Cited by 21
Abramovitz, M., & Metters, K. M. (1998) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)61087-8 · Cited by 11
Elliott, W. J. (2007) · Yearbook of Cardiology · doi:10.1016/s0145-4145(08)70031-5 · Cited by 8
The potential application of cyclo-oxygenase type 2 inhibitors to Alzheimer’s disease
Sandson, T. A., & Félician, O. (1998) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.7.4.519 · Cited by 2
Cited by
Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective
Bindu, S., Mazumder, S., & Bandyopadhyay, U. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114147 · Cited by 1,920
The Methylation Effect in Medicinal Chemistry
Barreiro, E. J., Kümmerle, A. E., & Fraga, C. A. M. (2011) · Chemical Reviews · doi:10.1021/cr200060g · Cited by 1,017
Harirforoosh, S., Asghar, W., & Jamali, F. (2014) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3vw2f · Cited by 960
Luo, Y., Zhao, X., Zhou, J., Yang, J., Zhang, Y., Kuang, W., Peng, J., Chen, L., & Zeng, J. (2017) · Nature Communications · doi:10.1038/s41467-017-00680-8 · Cited by 916
Advances in NSAID Development: Evolution of Diclofenac Products Using Pharmaceutical Technology
Altman, R., Bosch, B., Brune, K., Patrignani, P., & Young, C. (2015) · Drugs · doi:10.1007/s40265-015-0392-z · Cited by 493
Metadata
- Authors
- Rao, P., & Knaus, E. E.
- Venue
- Journal of Pharmacy & Pharmaceutical Sciences
- Publisher
- Frontiers Media SA
- Published
- 2008-09-20
- Volume
- 11
- Issue
- 2
- Pages
- 81
- ISSN
- 1482-1826 (ISSN-L)
- OpenAlex
- W1480874656
- Cited by
- 773
- References
- 113
- FWCI
- 15.52
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.